Sector News

Mylan, Lupin, others now in the mix for $1.1B Bayer derm buy

September 27, 2016
Life sciences

The list of drugmakers reportedly eying Bayer’s up-for-sale dermatology unit is growing even longer.

Mylan, New Jersey’s Leo Pharma and India’s Lupin, Cadila Healthcare and Torrent Pharmaceuticals are all weighing offers for the unit, which could bring in more than $1.1 billion for the German drugmaker as it looks to fund the $66 billion Monsanto acquisition it recently agreed to, Bloomberg reports.

Previous reports listed Nestle’s Galderma, Spain’s Almirall, India’s Sun Pharma, Teva, Allergan and Perrigo as potential suitors on the pharma side, while private equity firms such as KKR and Bain Capital have featured in the rumors, too.

The companies may not have much more time to decide whether to officially jump into the fray, though. Bids may be due as soon as this week, sources told the news service.

Both Mylan and Leo have made recent deals in the dermatology space. Bayer’s portolio–which includes eczema therapy Desonate and rosacea treatment Finacea–could bolster the €675 million worth of skincare assets Leo Pharma agreed last year to to buy from Japan’s Astellas, or those Mylan in May announced it would be buying with a $1 billion deal for Renaissance Acquisition Holdings.

Meanwhile, dermatology may not be the only divestment Bayer’s looking into. It’s also considering a potential divestment of its radiology business, which could fetch more than $3 billion, Bloomberg’s sources say.

Earlier this year, Sanford Bernstein analyst Jeremy Redenius suggested that a long-buzzed-about animal health sale could help Bayer drum up funds for the Monsanto buy, too.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach